All articles

My Daily Routine

What a typical day looks like for me.

A reader of The Good Investors sent me a message on LinkedIn recently asking what my daily routine is like. The reader mentioned that there’s likely to be strong interest in what goes on in a typical day for me. 

I have no idea if there really will be reader-interest in this topic. But I thought why not write about it anyway. A few years from now, it will also be fun to look back at this. 

So, I’m usually up by 7am or earlier. There are two things that I tend to do once I’m awake (besides washing up!): (1) Meditate, and (2) catch up on my favourite Twitter accounts. 

I don’t have an active Twitter account. But one of the great things about Twitter is that anyone can still access the platform and read tweets. Over the past 1.5 years or so, I’ve found Twitter to be an amazing place to catch up on great articles on life, business, technology, and more. It is also a wonderful resource for condensed pieces of knowledge. Some of the people I follow on Twitter are (in no particular order): 

Usually, there will be a lot of good articles shared through these accounts. I will then read through them.

As for meditation, I have found it to be profoundly useful in helping me deal with the stresses in life with equanimity. Sometimes, I meditate first before catching up on Twitter. Then there are days where I catch up on Twitter first, read the articles that pop up there, and then meditate. 

When both activities are done, it’s usually around 9:30am. This is when I start my reading/research/writing on companies for my just-launched fund’s investment activities, or for articles for The Good Investors. The wonderful thing about investing for a living, and writing an investment blog as a passion project, is that the work done for both activities often overlap in huge ways. I see it as killing two birds with one stone! 

I will usually stop around 12:30pm or 1pm for lunch, then resume the research/writing. Some days, I start working out around 4pm. But if I’m not working out at 4-ish, then I will continue my investment research/writing till 6:30pm or so and then work out. I try to exercise every day.

Dinner typically starts at 7:30pm for me. After dinner I will hang out with my loved ones. After which, I carry on reading till I sleep. Some days I will be watching Youtube before bed. It depends on my mood. But even when I’m watching Youtube, I often will think about something like “Hang on, from my morning reads, I remember Company ABC having a unique management team. Let’s do some research!”… And off I go into a rabbit hole. 

Bedtime for me is around 11:30pm or 12 midnight. And then it all starts again! 

My daily routine has changed over time. Just 3 years ago, exercising at the gym would be the first thing I do in the morning after waking up. But now I prefer to exercise at a time when my energy is waning (late afternoon or early evening). I prefer to use the time when my mind is the most alert for reading/research/writing. Who knows when my routine will change again. But for now, this is what works for me! 

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.

Can Novocure Revolutionise The Way Cancer is Treated?

Novocure could be changing the way cancer is treated. It sells a wearable device that has been shown to disrupt cancer cell reproduction.

Cancer is a brutal disease and one of the leading causes of death in the developed world. Worldwide, the disease struck more than 17 million people in 2018 with that figure expected to mushroom. 

One company that is doing its part in the fight against cancer is NovoCure Ltd (NASDAQ: NVCR).

Founded in 2000, NovoCure has developed a cancer therapy called tumour treating fields, which inhibits tumour growth and may causes cancer cells to die.

In this article, I take a look at the medical research behind its technology and whether NovoCure is a potential multi-bagger.

Technology behind Novocure

Novocure was founded 20 years ago by Professor Yoram Palti who believed that he could use electric fields to destroy cancer cells.

I don’t want to go too deep into the technicalities but to appreciate Novocure, it is important to understand the basics behind its technology.

In short, cellular proteins in cancer cells need to position themselves in a particular way during cell division in order for cells to divide. Tumour treating fields use alternating electric fields specifically tuned to target cancer cells, disorientating the position of the cell proteins and disrupting cell division.

It is equally important that tumour treating fields also do not stimulate or heat tissues and has minimal damage to healthy cells, with the only side effect being mild to moderate skin irritation.

From theory to practice

Novocure has done an excellent job of turning Professor Palti’s theory into real-life clinical practice. Today, tumour treating fields is approved in certain countries for the treatment of adults with glioblastoma and in the US for mesothelioma. These are two of the most difficult forms of cancer types to treat.

For instance, life expectancy for newly-diagnosed Glioblastoma, the most common type of brain cancer in adults is typically less than two years. 

Today, there is a growing body of research that shows that tumour treating fields therapy can extend the life expectancy of patients when it is used together with other therapies.

The chart from Novocure’s investor presentation shows the survival rate of patients with and without tumour treating fields (Optune) treatment.

Source: Novocure investor presentation 2020

Out of the cohort of 450 patients, 388 received a survival benefit from the use of tumour treating fields. The 5-year survival rate was 13% in the cohort that used tumour treating fields combined with chemotherapy (TMZ or Temozolomide) compared to just 5% in the cohort that used chemotherapy alone.

In fact, the efficacy and minimal side effect of Tumour treating fields as a therapy has led to the National Comprehensive Cancer Network promoting it to a category 1 recommendation for newly diagnosed Glioblastomas,

Growing the number of indications

Tumour treating fields as a therapy could potentially be used on a wide variety of other cancer types. As mentioned earlier, it is FDA approved for (1) recurrent and (2) newly diagnosed glioblastoma and received FDA-approval for (3) Mesothelioma last year.

On top of that, it is undergoing phase III trials for four other indications, namely (1) brain metastasis, (2) non-small cell lung cancer, (3) pancreatic cancer and (4) ovarian cancer. This could significantly increase the company’s addressable market opportunity.

It is also in Phase II trials for liver cancer and preclinical trials for a host of other cancer types. The charts below summarise where the company is at in terms of commercialising its product for the other indications.

Source: Nocovure Investor relations website

Source; Novocure Investor relations website

In its 2019 annual shareholder letter, CEO Asaf Danziger and executive chairman Bill Doyle, reiterated their commitment to innovation saying, 

“We are increasing investments in engineering efforts intended both to improve time on therapy and to maximize the energy delivered to patients’ tumours. Specifically, our teams are working to design and develop improvements to our transducer arrays and to our transducer array layout mapping software intended to increase Tumor Treating Fields intensity and, as a result, survival.

We believe innovation has the potential to improve patient outcomes and to extend our intellectual property protection into the future as we invent enhancements to our products. Our commitment to innovation resulted in 33 new patent applications in 2019, alone.”

From an investors point of view

From a medical standpoint, Novocure’s Tumour Treating Fields technology looks very promising. 

But as investors, we also want to see that the company has the finances to continue funding its research and can drive adoption to grow its revenue.

There are two things I want to see in a promising company like Novocure- (1) a solid balance sheet so that it does not need to raise too much capital to fund its growth and (2) at least some signs that the company is turning its FDA-approval into meaningful revenue growth.

Novocure has both.

The chart below illustrates its net revenues from 2016 to the first quarter of 2020.

Source: Novocure investor presentation 2020

Novocure has also partnered with a Chinese company, Zai, to launch its Tumour treating fields in China. The partnership is already starting to bear fruit with US$2 million in net revenue recorded in greater China in the first quarter of 2020, a 100% increase in from Q4 of 2019.

It is worth noting that Novocure turned operationally and free cash flow positive in 2019. Novocure also has a robust balance sheet with around US$332 million in cash, cash equivalents, short-term investments and restricted cash and no debt. 

Market opportunity

According to Novocure’s S-1 in 2015, Tumour treating fields is broadly applicable to a variety of solid tumours with an annual incidence of 1.1 million people in the United States alone.

Novocure charges around US$21,000 per month for Optune, its tumour treating fields device that is used to treat glioblastomas. Supposing that Novocure sells its other tumour treating fields products at a similar price range, Novocure will have a market opportunity of US$277 billion ($21,000 x 12 months x 1.1million patients) in the United States alone.

That’s of course assuming that Tumour Treating Fields therapy can be FDA-approved for the whole range of applications. 

Valuation

At the time of writing, Novocure had a market cap of US$6.3 billion. On the surface, that seems expensive if you use traditional metrics to value the company. Novocure only had US$351 million in net revenues and US$262 million in gross profits in 2019. 

Based on current share prices, it trades at 17.9 times 2019’s sales and 24 times gross profit. Those numbers are hard to stomach and would certainly be deemed expensive for most companies.

However, Novocure, to me, is not like most companies. 

In the most recent quarter, revenue grew 39% from a year ago. The growth figure could start to accelerate as its core markets mature and Tumour treating fields gains FDA-approval for other indications.

It is also worth remembering that based on my calculations it has a US$277 billion market opportunity. If it can penetrate just 5% of that, its current US$6.7 billion market cap will be a steal.

Final words

Novocure has all the makings of an excellent company. Its technology can potentially be used in a wide array of different indications and is already generating positive free cash flow.

It has a solid track record of growing revenue. Gaining FDA-approval for other use cases could potentially be a catalyst for much greater things for the company. With all that said, it does look like Novocure has all the ingredients for success.

That said, I do acknowledge that as with any biotech firm, there are risks. The risks that it cannot get FDA-approval for other indications or adoption of its product is slower than expected can hinder growth and can lead to other companies catching up with it.

The technology is also very new and widespread adoption will depend on how quickly Novocure can push clinicians to recommend it as a form of treatment. 

But despite these risks, to me, the probability and magnitude of the upside outweigh the risk. With its market cap still small compared to its total addressable market opportunity, I think if it can execute and fulfil its vast potential, Novocure could easily become a multi-bagger based on today’s price.

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.

How Should We Invest In A Low Interest Rate Environment?

The US benchmark interest rate is back to an all-time low. How should we invest, and what returns can we expect over the long run?

A few months back, the US Federal Reserve slashed its benchmark interest rates to between 0% and 0.25%. The last time it was this low was in late 2008, during the throes of the Great Financial Crisis. Now, with the near-term economic impact of the COVID-19 crisis still unknown, there’s also the possibility that the benchmark interest rate in the US could move into unprecedented negative territory.

This gives us investors a dilemma. In this low rate environment, should we invest in higher-returning but riskier asset classes, or stick to lower-risk but ultra-low-yielding investments?

The search for higher returns

Interest rates are an important determinant in the long-term returns of most asset classes. In a low-interest-rate environment, corporate bonds and treasuries naturally have low yields. Holding cash is an even less attractive proposition, with bank interest rates almost negligible.

In a bid to get higher returns, stocks may be the best option for investors.

How much is enough?

According to Trading Economics, interest rates in the US had averaged at 5.59% from 1971 to 2020. Meanwhile, the S&P 500 returned approximately 9.3% annually during that time. In other words, investors were willing to invest in stocks to make an additional 4% per year more than the risk-free rate.

This makes sense, given that stocks are also more volatile and are considered a riskier asset. Investors, therefore, will require a return-premium to consider investing in stocks.

But interest rates then were much higher than they are today. With the benchmark interest rate in the US now at 0% to 0.25%, what sort of expected returns must the stock market offer to make it an attractive option?

I can’t speak for everyone but considering the options we have, I think that as in the past 50 years, a 4% spread over the risk-free rate makes stocks sufficiently attractive.

The big question

So that naturally leads us to the next question. Can investing in the S&P 500 index at current prices give me a 4% premium over the current risk-free rate.

Sadly, I don’t have the answer to that. The S&P 500 is a basket of 500 stocks that each have their own risk-reward profile. With so many moving parts, it is difficult to quantify how the index will do over the long run. Similarly, other indexes are difficult to predict too.

However, I know that there are individual companies listed in the global stock markets today that could provide an annual expected return of much more than 4% over the risk-free rate.

By carefully building a portfolio out of such stocks, I think investors can navigate safely through the current low-interest environment and still come up with decent returns over the long term.

A few months ago, my blogging partner, Ser Jing, shared his investment framework that helped him build a portfolio of stocks that compounded at a rate that is meaningfully higher than 4% a year (19% to be exact) from October 2010 to May 2020. 

Using a sound investment framework, such as his, to build a portfolio may be all you need to navigate through this low-interest-rate climate.

DisclaimerThe Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.

Quick Thoughts on Glove Manufacturers

Glove manufacturers have seen their share prices climb to all-time highs in recent months because of Covid-19. Has the market gotten ahead of itself?

The glove manufacturing industry has been one of the few beneficiaries of the Covid-19 outbreak. Share prices of glove manufacturers have skyrocketed in the past few months (some are up more than 100%!) with many of them touching record highs earlier this month.

The share price performance is backed by solid business results as shown by the table below.

Source: Respective company’s earnings results

The four glove manufacturers I’ve studied – Riverstone, Top Glove, Hartalega, and Supermax – have seen sharp increases in revenue. These companies have not only benefited from a rise in sales volumes, but also an increase in the average selling prices of their gloves. The increase in demand has also resulted in their factories operating closer to full capacity, which have resulted in greater economies of scale and fatter margins. 

Growth to continue for the next few quarters

Although the spread of Covid-19 is slowing down in parts of the world, demand for rubber gloves is expected to remain high as authorities place greater emphasis on hygiene and prevent a rapid spread of the virus.

In its earnings results for the quarter ended 31 May 2020, Top Glove said: 

“The Group’s extraordinary performance was attributed to unparalleled growth in Sales Volume, on the back of the global COVID-19 pandemic. Monthly sales orders went up by some 180%, resulting in long lead times, which went up from 40 days to around 400 days, whereby orders placed now would only be delivered over a year later.

However, Top Glove has endeavoured to allocate capacity to as many countries as possible, to ensure its life-saving gloves reach those most in need, while also prioritising its existing customers. It also accommodated requests from various governments of hard-hit countries who approached the Group directly to procure gloves.”

Will the growth last?

The near-term outlook for glove manufacturers looks distinctly positive but the question is: How long will it last?

Based on comments made by Top Glove, the glove manufacturing industry as a whole probably has a large backlog of orders. This will provide them with steady revenue streams and high margins for the next few quarters. However, what happens after this? 

It is likely that this current spike in orders is a one-off occurrence. Some countries are stocking up in case there is a second wave of Covid-19, while others that have yet to feel the full effects of the pandemic are preparing for the worst. But when this blows over, glove demand could fall- maybe not to pre-pandemic levels – but likely below the current unsustainably high levels.

Frothy valuations

As mentioned earlier, glove manufacturers have seen their share prices skyrocket recently.

The table below illustrates the price-to-annualised earnings ratios of the same four glove manufacturers I had mentioned. I used the most recent quarterly earnings to calculate the annualised earnings for these companies.

Source: Author’s calculation using figures from Google Finance

As you can see, each of these companies have an annualised P/E ratio of close to 30 or higher. Although I understand the optimism surrounding glove manufacturers, to me, their share prices have surged to what seems like rich valuations.

There is also the risk that if demand falls, the glove manufacturers will see average selling prices drop to more normal levels leading to lower gross margins.

I also want to point out that part of the expansion in the glove manufacturers’ profit margins was the lower price of butadiene, a key raw material used in the production of nitrile-based gloves. As glove manufacturers have little control over the price of this commodity, there is an additional risk that if butadiene prices return to previous high levels, profit margins will decline.

Final words

The stars seem to have aligned for glove manufacturers. Not only has demand increased, but gross margins have also been boosted by lower raw material prices. It is also likely that the demand for rubber gloves will continue to be high for an extended period of time. And with the large backlog of orders, glove manufacturers will have their hands full for the next few quarters.

However, there are still risks worth noting. Current fat profit margins may not be sustainable over the longer term. When capacity eventually catches up to demand, average selling prices are likely to fall and margins will normalise. 

On top of that, the glove manufacturers’ share prices have surged to all-time highs and they are currently sitting on extremely rich valuations. To me, it seems that much of the upcoming profit growth of glove manufacturing companies has already been priced in.

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.

Webinar: “Active vs Passive Investing: Lessons Learned with Ser Jing”

A recent webinar with Samuel Rhee, Chairman and Chief Investment Officer of Endowus, to talk about active investing versus passive investing.

Endowus is a roboadvisor based in Singapore. In March 2020, Jeremy and myself had the pleasure of meeting Samuel Rhee and Chiam Sheng Shi. They are Endowus’s Chief Investment Officer and Personal Finance Lead, respectively. 

On 17 June 2020, I participated in a webinar hosted by Endowus, where Sam and I talked about active investing and passive investing. I want to thank Sam and the Endowus team (especially Sheng Shi) for their kind invitation. Sam is one of the wisest investors I’ve met, and I learnt a lot from him in our 1.5 hour conversation.

Active versus passive is one of the hottest topics in the investing world today and Sam and I covered a lot of ground during our session. Check out the video of our chat below!

Some of things we talked about include:

  • My journey in active investing
  • Sam’s journey in the active investing world before Endowus
  • The “Three P’s of Institutional Investing”
  • Advantages that institutional investors have
  • Endowus’s focus on doing three things very well for their investors: Access to great investment products; providing good evidence-based investing advice; and lowering costs for investors
  • The foundational building blocks of Endowus’s service. In particular, Sam dug deep into Endowus’s innovative full trailer-fee-rebates and how that benefits individual investors. Trailer fees are fees that a fund manager pays to an investment advisor or investment products distributor – and these fees come directly from the investors who purchase the funds. I admire Endowus for rebating the trailer fees it receives, because these fees are a huge hidden cost that eats into the returns investors earn; the presence of trailer fees is also a big reason why fund management fees are so high in Singapore.
  • Endowus’s investment philosophy:
    • Maximise returns by minimising cost
    • Enduring belief in power of markets
    • Time in markets vs market timing
    • Asset allocation is everything
    • Strive for the efficient frontier
    • Diversification improves risk-return
    • Optimise based on personal risk tolerance
    • Know your limitations
  • My investment philosophy
  • Traits of a good active investor
  • Etymology for the words “invest” and “投资” (Mandarin word for invest) and how this may be affecting investor-behavior in Western and Eastern societies.
  • Capital-flows into active vs passive funds
  • Evidence showing why active investing often fails
    • My thoughts on why it’s still possible to beat the market
  • The reasons why previously successful active managers end up underperforming
  • My book recommendations for new investors: Thinking, Fast and Slow by Daniel Kahneman, and One Up On Wall Street by Peter Lynch.
  • The importance of having low costs in the investment products we’re investing in
  • How Endowus provides industry-leading low cost investment solutions for investors
  • Investors’ behavioural mistakes during the COVID-19-driven market panic seen in the first half of this year
  • The important distinction to be made between the terms “active” and “passive” when applied to investing. Passive investing is often understood to be the use of passively-managed index funds as the preferred investing vehicle. But is someone who often jumps in and out of these index funds a truly passive investor? Is a person who picks stocks, but who then holds these stocks patiently for years, active or passive? 
  • How I manage cash in an investment portfolio
  • On hindsight, are there any changes to our investments we wish we had made during the market panic in the first half of 2020
  • Endowus’s desire to constantly improve their offerings for investors whenever they find better investment products.

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.

What We’re Reading (Week Ending 21 June 2020)

The best articles we’ve read in recent times on a wide range of topics, including investing, business, and the world in general.

We’ve constantly been sharing a list of our recent reads in our weekly emails for The Good Investors.

Do subscribe for our weekly updates through the orange box in the blog (it’s on the side if you’re using a computer, and all the way at the bottom if you’re using mobile) – it’s free!

But since our readership-audience for The Good Investors is wider than our subscriber base, we think sharing the reading list regularly on the blog itself can benefit even more people. The articles we share touch on a wide range of topics, including investing, business, and the world in general.

Here are the articles for the week ending 21 June 2020:

1. The Age of We Need Each Other – Charles Eisenstein

It was a painful yet beautiful clarifying experience that asked me, “Why are you doing this work? Is it because you hope to become a celebrated intellectual? Or do you really care about serving the healing of the world?” The experience of failure revealed my secret hopes and motivations.

I had to admit there was some of both motivations, self and service. OK, well, a lot of both. I realized I had to let go of the first motive, or it would occlude the second. Around that time I had a vision of a spiritual being that came to me and said, “Charles, is it really your wish that the work you do fulfill its potential and exercise its right role in the evolution of all things?”

“Yes,” I said, “that is my wish.”

“OK then,” said the being. “I can make that happen, but you will have to pay a price. The price is that you will never be recognized for your role. The story you are speaking will change the world, but you will never get credit for it. You will never get wealth, fame, or prestige. Do you agree to pay that price?”

I tried to worm my way out of it, but the being was unyielding. If it was going to be either-or, how could I live with myself knowing in my heart of hearts I’d betrayed my purpose? So I consented to its offer.

2. John Collison – Growing the Internet Economy – [Invest Like the Best, EP.178] – Patrick O’Shaughnessy and John Collison

Yeah, again, just like people kind of had a hard time believing that we weren’t done with the payment systems that we had at the time. Similarly, I think people don’t really intuit this. I mean, if you look at the raw numbers, the internet economy is a very small fraction of the overall economy depending on who you believe, five, 6%, something like that, but the vast majority of internet, of the economic activity is not internet enabled. I think it’s fairly clear to all of us that that is going to flip. We’re going to end up with actually a majority that’s internet enabled, but that means we’re really at a shockingly early point in that Sigmoid growth curve.

The thing that gets me excited, and one of the things that we spent a lot of time thinking about at Stripe and trying to drive is what the second order effects are of that shift, and I think people spend lots of time thinking about first order effects of technology changes and so if you were an analyst looking at the growth of computers in the fifties and sixties, you might be wondering what are the effects going to be of computers getting faster? Presumably you’d say, well, banks are going to be able to run their calculations faster and airlines are going to be able to handle even more routes in the route calculation computers.

You’d look as what computers were already used for and just kind of project that forward more and faster. You would never forecast video games. I mean, to someone in the fifties, it would seem absurd, the notion that you could have so much excess computing power and it’s so cheap that we’re just going to use this for this wildly wasteful rendering of triangles. I don’t know if you saw the Unreal Five demo, but imagine showing that to somebody in the 1950s. It really, I think their brain might have exploded, or similarly with smartphones…

…  I mean, I still find technology some of the most interesting, one of the most interesting places to look, because what I find so exciting about technology is from a business point of view, it’s positive-sum, right? So many other businesses are essentially, I mean, they learn not to talk about them this way, but there’s all these like business euphemisms for the fact that, there’s a fixed amount of supply in this industry and we’re getting really good price discipline. That’s one of these like investor-y euphemisms and for not competing too much on price or revenue optimization and things like that, as you look at something like real estate, in many kinds of parts of the world, barriers to building mean that part of what makes it a good business is the fact that there’s a fixed number of assets that can be monetized.

3. We Can Protect the Economy From Pandemics. Why Didn’t We? – Evan Ratliff

Kraut, however, had an even more ambitious idea in mind. What if, instead of simply hedging its own life insurance business in the case of a pandemic, Munich Re could use the same concept to insure other businesses against them? Business interruption insurance, the policies that protect companies against income losses from disasters like fires or hurricanes, often explicitly excluded disease. (And when it didn’t, insurers could still use the ambiguity to deny claims.) The risk was thought to be too large, too unpredictable to quantify. But Munich Re had already proven it could cover its own life insurance risk in pandemics, and now it had a partner in Metabiota that specialized in seemingly unpredictable outbreaks. What if they could create and sell a business interruption insurance policy that covered epidemics, starting with acutely vulnerable industries like travel and hospitality? They could then pass on the payout risk from those policies to the same types of investors who had bought their life risk. “There is a bit of financial alchemy to the whole thing,” Wolfe told me later. “You really are creating something from nothing.”

At the same time, Wolfe had been working to operate Metabiota more like a technology company. In 2015, he hired Nita Madhav, an epidemiologist who’d spent 10 years modeling catastrophes at a company called AIR Worldwide, one of a handful of firms the insurance industry relies on to compute extreme risks. (Munich Re, in fact, had worked with AIR epidemiological models in its life insurance calculations.) Madhav’s mandate at Metabiota was to build the industry’s most comprehensive pandemic model. Her team, which eventually grew to include data scientists, epidemiologists, programmers, actuaries, and social scientists, began by painstakingly gathering historical data on thousands of major disease outbreaks dating back to the 1918 flu. Her colleagues had recently created what they called the Epidemic Preparedness Index, an assessment of 188 countries’ capacity to respond to outbreaks. Together, the two efforts informed an infectious disease model and software platform. A user could begin with a set of parameters around a hypothetical virus—its geographic origin point, how easily it was transmitted, its virulence—and then run scenarios exploring how the disease spread around the world. The goal was a model that could, for example, help a manufacturer understand how a disease might impact its supply chain or a drug company plan for how a treatment would need to be distributed.

4. The Observer Effect: Marc Andreessen– Sriram Krishan

Well, I will pick three! It’s kind of the holy trinity of our modern dilemma. It’s health care, it’s education and it’s housing. It’s the big three. So basically, what’s happened is the industries in which we build like crazy, they have crashing prices. And so we build TVs like crazy, we build cars like crazy, we make food like crazy. The price on all that stuff has really fallen dramatically over the last 20 years which is an incredibly good thing for ordinary people. Falling prices are really, really good for people because you can buy more for every dollar.

There are two ways here: you get paid more or everything you buy is cheaper. And people always really underestimate, I think, the benefits of everything getting cheaper. And so the stuff that we actually build is getting cheaper all the time. And that’s fantastic. The stuff we *don’t* build, and very specifically, we don’t have housing, we’re not building schools, and we’re not building anything close to the health care system that we should have – for those things the prices just are skyrocketing. That’s where you get this zero sum politics.I think people have a very keen level of awareness. They can’t put it into formal economic terms but they have a keen awareness of the markers of a modern western lifestyle. It’s things like – I want to be able to own a house, I want to live in a nice neighborhood and I want to be able to send my kids to a really good school and I want to have really good health care.

And those are the three things where the price levels are increasingly out of reach. However we built those systems in the past, it’s failing us. And so we need to rethink. Quite literally, it’s like, okay, where are the schools? Where are the hospitals? Where are the houses?

5. The Resilience Of Markets – Jamie Catherwood

Wall Street and American markets have endured the tests of many challenging episodes in history. The Buttonwood Agreement was signed in 1792, and since then the United States of America has experienced its fair share of wars, recessions, political upheaval, Presidential assassinations, natural disasters, disease, terrorist attacks, and more. Despite all these adversities, however, the institution of Wall Street and US markets have held firm as a bastion of American finance. Take a moment to really consider this feat, as it’s truly remarkable. Much has changed in the centuries since the Buttonwood Agreement was signed by 24 stockbrokers outside of 68 Wall Street on May 17th, 1792. Yet, much has stayed the same. If you read any archival document from the years between 1792 and 2020, it is quickly evident that investors have always found reasons to fear the continued function of American markets due to some new policy or action by an institution.

However, New York is still considered the global capital of financial markets, and Wall Street continues to be revered by investors worldwide. So, this week’s Sunday Reads will focus on the first decades of financial markets in the United States, and the groundwork that our predecessors laid for investors today.

6. Five Tips for Recovering From Covid-19 Panic Selling – Barry Ritholtz

No. 1. Recognize what happened: What motivated you to sell? Was it something you heard on the news? An emotional impulse? Did you give any thought to how selling fit in your broader investment strategy? Or was it merely an itch that had to be scratched?

Figuring out what goes into your own decision-making is the key to reducing mistakes. Analyze your process: Determine what factors should have an impact when making buy and sell decisions. Then, face up to what actually drives those decisions. If there is a mismatch between those two, recognize it and make adjustments.

If you don’t know how you got lost, what is to stop you from getting lost the next time this happens? Remember, there always is a next time.

7. Same As It Ever Was – Morgan Housel

The nuclear bomb was developed to end World War II. Within a decade, America and the Soviets had bombs capable of ending the world – all of it.

But there was a weird silver lining to how deadly these bombs were: countries were unlikely to use them in battle because they raised the stakes so high. Wipe out an enemy’s capital city and they’ll do the same to you 60 seconds later – so why bother? John F. Kennedy said neither country wanted “a war that would leave not one Rome intact but two Carthages destroyed.”

By 1960 we got around this predicament by going the other way. We built smaller, less deadly nuclear bombs. One, called Davy Crocket, was 650 times less powerful than the bomb dropped on Hiroshima, and could be fired by one person like a bazooka. We built nuclear landmines that could fit in a backpack, with a warhead the size of a shoebox.

These tiny nukes felt more responsible, less risky. We could use them without ending the world.

But they backfired.

Small nuclear bombs were more likely to actually be used in combat. That was their whole purpose. They lowered the bar of justified use.

It changed the game, all for the worse.


Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.

Should a Company Ever be Worth Less Than Its Net Cash?

In the stock market, you may find companies trading at less than the cash it owns. But they don’t neccessarily make good investments. Here’s why.

When I first started investing, the “deep value” style of investing resonated with me. This style involves buying shares in a company that is trading at a discount to its net cash. It seemed like a sensible thing to do.

Buying a dollar for less than a dollar sounded like a common-sense approach that couldn’t go wrong.

But the net cash is just one aspect of a company. The company could be burning cash at unsustainable rates and destroying shareholder value. In this case, buying said company below its net cash will still turn out to be a bad investment.

Given this, investing in a company should not be based purely on its net cash but on the future cash flows that the company can generate. 

How can a company be worth less than the cash it owns?

This is why I believe that it may even be possible for a company to be worth less than the net cash on its balance sheet.

If a company is burning money every year and management does not make any changes, it will eventually run out of cash. Shareholders will then be left with nothing. In other words, a company with a lot of cash but a terrible business model that does nothing but destroy shareholder value should very reasonably trade less than its net cash. The example below can illustrate my point.

Company ABC has $10 million in cash and no debt. However, it is going to burn cash at a rate of $1 million a year over the next 10 years. How much should this company be worth?

Using the discounted free cash flow method and an 8% discount rate on future cash flows, the company is worth only $3.29 million. That’s a 67% discount to its net cash.

Valuation screens only tell half the story

So how should we apply this to our investment decisions? I think the key takeaway is that we should not base our investment decisions solely on the valuation of a company.

A company may look cheap using traditional valuation metrics, but in reality, it may not be cheap if you take into account the future cash flow of the company.

For example, even the trailing price-to-earnings ratio may not be a good indicator of a company’s cheapness. “Trailing earnings” is a historical figure. John Huber of Saber Capital Management brought up a great point in a recent video interview.

In the past, trailing earnings for many companies were a good guidepost for future earnings. This was why the price-to-earnings multiple was used to value a company.

However, the divergence today between future earnings and past earnings is huge. There are numerous companies being disrupted, while well-run technology companies are building new and rapidly growing markets for themselves. In today’s world, past earnings may not be a good representation of future earnings for many companies anymore.

How to apply this principle?

As investors, our goal is to buy companies at a discount to their real value. But that value can no longer be derived largely from using metrics such as the price-to-book or price-to-trailing earnings ratios. We need to look at the company’s likelihood in generating future free cash flow.

Instead of focusing my energy looking at historical ratios, I try to dig deep into a company’s business, its competitive moat, market opportunity, and the ability of management to grow or at the very least maintain said company’s cash flow. By doing so, I get a better understanding of how much free cash flow a company could generate in the future and the probability it can achieve these projections.

These factors will eventually determine the real value of a company in the long-term, and not its historical earnings nor book value.

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.

Thoughts On Datadog Inc: A Best-in-Class SaaS Company

Datadog is one of the fastest growing SaaS companies. But with its stock trading at around 45 times its annual revenue run rate, is it too expensive?

As a B2B (business-to-business) cloud software provider, Datadog Inc (NASDAQ: DDOG) may not be a household name to non-developers and IT engineers. However, it definitely caught my attention.

The monitoring and analytics platform for developers, IT operations, and business users is one of the fastest-growing software companies and has some of the best-in-class metrics to boot.

Despite less than a year as a public company, Datadog’s share price is already double from its first trading day in September 2019. In this article, I share my thoughts on Datadog.

A huge market opportunity

Companies that house their data in the cloud can end up with a complex web of data and information that is difficult to monitor. This is where Datadog’s platform can help. It provides monitoring services across public cloud, private cloud, on-premise, and multi-cloud hybrid environments.

Datadog estimates that the IT Operations Management market will represent a US$37 billion market opportunity in 2023, with the company’s services addressing US$35 billion of that.

Compare that to Datadog’s 2020 first-quarter annual revenue run-rate of around US$524 million, and you can see just how much potential lies ahead.

Growing into its own

Datadog is doing a great job in executing its growth strategy. The software-as-a-service (SaaS) company saw its revenue grow by 98% and 83% in 2018 and 2019 respectively.

Source: Datadog IPO prospectus

In the first quarter of 2020, revenue increased by 87% year-over-year as the number of large customers (with an annual run rate of US$100,000 or more) surged to 960 from 508 a year ago.

Moreover, management expects revenue to increase to between US$555 million and US$565 million for the whole of 2020.

Growing customer base

But, to me, the most appealing thing about Datadog’s business is that the company has some of the best-in-class metrics for SaaS companies.

Datadog has recorded gross margins of 75% to 77% over the past three years, and even had positive GAAP (generally accepted accounting principles) operating income in the first quarter of 2020.

Recording a profit is pretty amazing for a company that is growing as fast as Datadog is.

The reason why Datadog can be so operationally efficient even at this high rate of growth is that it has one of the best-in-class customer acquisition cost (CAC) ratios. The CAC payback period measures how long the company takes to earn back the marketing dollars spent to acquire a new customer. It is calculated as the implied annual run rate gross margin from new customers divided by sales and marketing spend of the prior quarter.

Alex Clayton, general partner at venture capital firm Meritech Capital, recently provided a fantastic chart comparing Datadog’s CAC payback period against other listed SaaS companies (note, the lower the number, the better).

Source: Medium.com article by Alex Clayton

From the chart, you can see that Datadog recovered all its marketing cost to acquire a new customer in around 10 months. That’s only behind video-conferencing software provider Zoom, and well below the 30-month median for SaaS companies.

Customers spending more on its platform

Datadog’s existing customers also continually spend more on its platform. In the first quarter of 2020, Datadog’s dollar-based net retention rate (DBNRR) was above 130% for the 11th consecutive quarter. The DBNRR measures the change in spending for all of Datadog’s customers a year ago compared to the same group of customers today; it includes positive effects from upsells and negative effects from downgrades and customers who leave.

Datadog charges customers base on usage, so the more users (the customer’s employees) that use the platform, the more the customer pays Datadog. 

In addition, Datadog has consistently introduced more products on its platform. Datadog uses a land-and-expand growth model. The company first wins customers over to use one product before cross-selling other products to them.

The chart below, taken from Datadog’s IPO prospectus, shows the annual revenue run rate of cohorts (customers that started using the platforms) from 2012 to 2018.

Source: Datadog S-1

As you can see, each colour on the graph fattens over the years. This means that the cohorts are collectively spending more money on Datadog’s platform.

Robust balance sheet

Datadog raised around US$648 million during its September 2019 IPO. As of March 2020, Datadog had US$794 million in cash, cash equivalents, and marketable securities and no debt. This is a great financial position.

In addition, Datadog announced in late May 2020 that it is raising US$650 million through a convertible notes offering. The conversion price of US$92.30 per share represents a 21% premium to the company’s share price at the time of writing.

The offering should further strengthen Datadog’s balance sheet. The convertible price after 5 years should not dilute shareholder interests by too much as well. As the company is already free cash flow positive (more on this below), I expect management to use the new-found cash to make strategic acquisitions to improve its core offering, or invest in R&D to launch new products.

Free cash flow 

As mentioned above, Datadog is already generating free cash flow. In fact, the company generated positive operating cash flow in 2017, 2018, and 2019; and had positive free cash flow in 2018 and 2019. In the first quarter of 2020, Datadog had US$19.3 million in free cash flow.

That’s equivalent to a free cash flow margin of 14.7%, decent for a company that is seeing such strong growth.

As the company grows, I expect Datadog’s free cash flow margin to widen and easily settle at 30% or more.

History of successful innovation and new products

Much of Datadog’s success has come from its constant innovation and creation of new products. The firm initially offered just infrastructure monitoring but soon expanded its service to monitor the entire technology stack.

This single pane view of the entire technology stack proved extremely popular and is one of the reasons why the company’s DBNRR is so high.

Going forward, innovation and technology upgrades will be key in ensuring that Datadog maintains its market position in this highly competitive space.

Final words

Datadog has the potential to become one of the top dogs in its industry.

But there are also risks such as execution risk and the threat of competition. It also hard to ignore Datadog’s extremely rich share price: The company’s market capitalisation is around 45 times its annual revenue run rate (based on revenue for 2020’s first quarter). This means that a lot of Datadog’s future growth is already being baked into its share price.

However, if Datadog manages to fulfill its potential and captures just 10% of its market opportunity, I think its future market capitalisation will be much higher than it is today.

Moreover, given its recurring income stream, position as a leading player in its space, high margins, operational efficiency and history of innovation, I think Datadog has a good chance of rewarding shareholders five to ten years down the road.

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.

*Editor’s note: The article mistakenly stated that the free cash flow for the first quarter of 2020 was US$23 million and free cash flow margin was 17.3%. However, the correct figures are 19.3% and 14.7%. The article has since been updated to reflect that.

Why We Do What We Do

Investing-disasters that affect individual investors are often preventable through investor education. This is why The Good Investors exists.

I woke up at 6:15am this morning. One of the first few things I saw on the web shook me. Investor Bill Brewster wrote in his Twitter account that his cousin-in-law – a 20 year-old young man in the US – recently committed suicide after he seemed to have racked up huge losses (US$730,000) through the trading of options, which are inherently highly-leveraged financial instruments. 

A young life gone. Just like this. I’ve never met or known Bill and his family before this, but words can’t express how sorry I am to learn about the tragedy.

This painful incident reinforces the belief that Jeremy and myself share on the importance of promoting financial literacy. We started The Good Investors with the simple goal to help people develop sound, lasting investing principles, and avoid the pitfalls. Bill’s cousin-in-law is why we do what we do at The Good Investors. 

In one of my earliest articles for The Good Investors, written in November 2019, I shared an article I wrote for The Motley Fool Singapore in May 2016. The Fool Singapore article contained my simple analysis on the perpetual securities that Hyflux issued in the same month. I warned that the securities were dangerous and risky because Hyflux was highly leveraged and had struggled to produce any cash flow for many years. I wish I did more, because the perpetual securities ended up being oversubscribed while Hyflux is today bankrupt. The 34,000 individual investors who hold Hyflux’s preference shares and/or perpetual securities with a face value of S$900 million are why we do what we do at The Good Investors. 

Whatever that happened to Bill’s cousin-in-law and the 34,000 individual investors are preventable with education. They are not disasters that are destined to occur.  

Jeremy and myself are not running The Good Investors to earn any return. Okay, maybe we do want to ‘earn’ one return. Just one. That people reading our blog can develop sound, lasting investing principles, and avoid the pitfalls. “A candle loses nothing by lighting another candle” is an old Italian proverb. We don’t lose anything by helping light the candle of investing in others – in fact, we gain the world. This is why we do what we do.

R.I.P Alex. 


Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.

A Useful Observation For Sembcorp Industries Shareholders: The Troubling State Of Its Energy Business

Sembcorp Industries (SGX: U96) dominated the business headlines in Singapore last week. The utilities and marine engineering conglomerate announced on 8 June 2020 that it would be completely spinning off its marine engineering arm – Sembcorp Marine (SGX: S51) – through a complex deal.

As part of the deal, there will be an injection of capital into Sembcorp Marine via a rights issue. Prior to the announcement, Sembcorp Marine was already a listed company in Singapore’s stock market, but it had Sembcorp Industries as a majority shareholder.

I won’t be explaining the deal in detail because others have already done so. My friend Stanley Lim has created a great video describing the transaction for his investor education website Value Invest Asia. Meanwhile, another friend of mine, Sudhan P, has written a great piece on the topic for the personal finance online portal Seedly. 

What I want to do in this article is to share an observation I have about the state of Sembcorp Industries’ business. I think my observation will be useful for current and prospective Sembcorp Industries shareholders.

The market cheers 

On the day after the Sembcorp Marine spin-off was announced, Sembcorp Industries’ share price jumped by 36.6% to S$2.09. So clearly, the market’s happy that Sembcorp Industries can now be a standalone utilities business (the company has other small arms that are in urban development and other activities, but they are inconsequential in the grand scheme of things). It’s no surprise.

Sembcorp Marine’s business performances have been dreadful in recent years. The sharp decline in oil prices that occurred in 2014 – something not within Sembcorp Marine’s control – has been a big culprit. Another key reason – a self-inflicted wound – was Sembcorp Marine’s decision to load up on debt going into 2014. The table below shows Sembcorp Marine’s revenue, profit, cash, and debt from 2012 to 2019:

Source: Sembcorp Marine annual reports

Getting rid of Sembcorp Marine will allow Sembcorp Industries’ utilities business (the segment is named Energy) to shine on its own. But there’s a problem: The economic quality of the Energy segment has deteriorated significantly over time. This is the observation I want to share. Let me explain.

Low energy

There are two key reasons why I think Sembcorp Industries’ Energy segment has gone downhill. 

First, over the six year period from 2013 to 2019, the Energy segment’s revenue and power production and water treatment capacities all grew – the power production capacity even increased substantially. But the segment’s profit did not manage to grow. In fact, it had declined sharply. Sembcorp Industries does report a separate profit figure for the Energy segment that excludes exceptional items. But the exceptional items are often gains on sale of assets and/or impairment of asset values. To me, these exceptional items are not exceptional; they reflect management’s day-to-day decision-making in allocating capital.

The table below shows the Energy segment’s revenue, profit, power capacity, and water-treatment capacity in each year from 2013 to 2019:

Source: Sembcorp Industries’ annual reports

Second, the Energy segment’s return on equity has fallen hard from a respectable 19.3% in 2013 to a paltry 5.3% in 2019. Here’s a table illustrating the segment’s return on equity for this time period:

Source: Sembcorp Industries’ annual reports

The sharp fall in the Energy segment’s return on equity, coupled with the decline in profit, suggests that the economic quality of the segment has worsened materially over the past few years. 

Some final words

It’s unclear to me how much of the Energy segment’s power and water capacities were actually in operation as of 2013 and 2019. So it’s highly possible that most of the increase in the capacity-figures seen in the period are mostly for projects that are still under development.

If this is the case, then there may still be a big jump in the Energy segment’s profit and return on equity in the future. But if it isn’t, then the business performance of the Energy segment in the past few years is troubling. If the Energy segment’s numbers can’t improve in the future, the overall picture for Sembcorp Industries still looks overcast to me even if Sembcorp Marine is no longer involved.

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.